Theranostics in the management of prostate cancer: from concept to clinical practice
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2026.2737765 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Kannan Sridharan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiopharmaceuticals. Die Arbeit nennt 136 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Radiotheranostics, integrating diagnostic imaging with targeted radiotherapy using molecularly matched radioactive agents, has emerged as a transformative approach in the management of prostate cancer. Prostate-specific membrane antigen (PSMA) is the dominant clinically validated target, and PSMA-targeted radioligand therapy has rapidly reshaped the treatment landscape across disease states. AREAS COVERED: This is a comprehensive overview of the prostate cancer theranostics landscape, with a primary focus on PSMA. We synthesized evidence from landmark randomized trials, guideline documents, and emerging data on alpha-emitting agents, combination strategies, and next-generation constructs. Literature search encompassed pivotal phase II/III trials, guideline documents, and contemporary mechanistic studies. Patient selection, distinguishing clinical-trial eligibility, regulatory indications, and guideline recommendations, is critically appraised. EXPERT OPINION: PSMA-targeted radioligand therapy has fundamentally reshaped the treatment paradigm, with [177Lu]Lu-PSMA-617 established in PSMA-positive metastatic castration-resistant prostate cancer and now expanding into earlier disease states, including metastatic hormone-sensitive prostate cancer. The future lies in biomarker refinement, rational combinations with poly(ADP-ribose) polymerase inhibitors, androgen receptor pathway inhibitors, and immunotherapy, and next-generation platforms including alpha-emitters and bispecific agents. Multidisciplinary integration and structured monitoring will be essential for optimizing outcomes as theranostics becomes a sequence-defining therapeutic platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain.
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Bahrain Defence Force Royal Medical Services, Riffa, Bahrain.
- ARON Research Foundation ETS, Macerata, Italy.
- Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital Pilsen, Charles University, Pilsen, Czechia.
- Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia.
ORCID-Profile: Kannan Sridharan
Zitieren
APA
Sridharan, K., Alonso-Gordoa, T., Sivaramakrishnan, G., Cerrillo, J. M., Fiala, O., Rehan, F., Mena Cortes, D., & Santoni, M. (2026). Theranostics in the management of prostate cancer: from concept to clinical practice. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2737765
Vancouver
Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM, Fiala O, Rehan F, et al. Theranostics in the management of prostate cancer: from concept to clinical practice. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2737765
BibTeX
@article{Sridharan2026,
author = {Sridharan, Kannan and Alonso-Gordoa, Teresa and Sivaramakrishnan, Gowri and Cerrillo, Javier Molina and Fiala, Ondrej and Rehan, Farah and Mena Cortes, Danny and Santoni, Matteo},
title = {Theranostics in the management of prostate cancer: from concept to clinical practice},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2737765}
}
EUVIMED